The critical role of HIBCH in pulmonary arterial hypertension

Related Experiment Video

Updated: Mar 9, 2026

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

11.4K

Boji Wu1, Tingting Tian1, Yuxiang Liu1

  • 1Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, China.

Toxicology and Applied Pharmacology
|March 7, 2026
PubMed

Lactate produced during glycolysis plays a critical role in pulmonary arterial hypertension (PAH) by mediating protein lactylation and other molecular effects. Targeting lactylation-related signaling holds significant promise for the treatment of PAH. Therefore, we aimed to investigate lactylation-associated gene signatures and identify the critical role of hub genes. Transcriptomics analysis and mendelian randomization (MR) were applied to screen hub lactylation-related genes. 3-hydroxyisobutyryl-CoA hydrolase (HIBCH) was identified as a hub lactylation-related gene. HIBCH was significantly upregulated in platelet-derived growth factor (PDGF) stimulated pulmonary arterial smooth muscle cells (PASMCs) and lung tissues in PAH. MR analysis revealed that HIBCH upregulation correlated with higher PAH risk. Subsequently, the cell viability, proliferation and migration were detected to elucidate the effects of HIBCH on PASMCs. HIBCH knockdown markedly reduced the PDGF-induced lactate production, proliferation and migration in PASMCs. Further, cyproheptadine was screened as a potential HIBCH inhibitor. Cyproheptadine suppressed PASMCs proliferation and alleviated the monocrataline-induced pulmonary hypertension in vivo. Together, we identified the lactylation-related gene HIBCH as a risk factor for PAH and provided a novel therapeutic candidate for the treatment of PAH.

Keywords:
HIBCHLactylationMendelian randomizationPulmonary arterial hypertension

More Related Videos

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model07:10

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model

Published on: June 3, 2020

10.9K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.9K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
609
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
674
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
751
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
593
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
568
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
564